LABT
NASDAQLakewood-Amedex Biotherapeutics Inc.
Price$0.39-0.07 (-14.37%)
01:45 PM07:45 PM
News · 26 weeks21-69%
2025-12-212026-06-14
Mix2190d
- SEC Filings8(38%)
- Other6(29%)
- Insider6(29%)
- Leadership1(5%)
Latest news
21 items- SECLakewood-Amedex Biotherapeutics Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)
- PRLakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor ForumSARASOTA, Fla., June 16, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT, the ", Company", )), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that Kelvin Cooper, Ph.D., Chief Executive Officer and Senior Vice President of Research, will present at the Life Sciences Virtual Investor Forum on June 25, 2026. Presentation Details:Event:Life Sciences Virtual Investor ForumDate/TimeJune 25, 2026, at 11:30, AM EDTWebsiteRegistration Link"We look forward to presenting Lak
- PRLakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot UlcersPatent portfolio now includes 71 granted patents and 28 pending patent applications, covering composition of matter, formulation, and use patentsSARASOTA, Fla., May 27, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT, the ", Company", )), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced an expansion of its global intellectual property portfolio with the issuance of two patents, one each in Australia and New Zealand respectively.
- SECSEC Form 424B3 filed by Lakewood-Amedex Biotherapeutics Inc.424B3 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)
- SECSEC Form 424B3 filed by Lakewood-Amedex Biotherapeutics Inc.424B3 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)
- SECSEC Form 10-Q filed by Lakewood-Amedex Biotherapeutics Inc.10-Q - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)
- PRLakewood-Amedex Biotherapeutics Announces Positive Data for the Advancement of Lead Candidate, Nu-3, in Infected Diabetic Foot UlcersKey formulation, delivery and manufacturing steps completed in preparation for planned Phase 2 clinical trial SARASOTA, Fla., May 18, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT, the ", Company", )), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced positive data for its lead compound, Nu-3, as it advances towards a Phase 2 trial. Nu-3 is being developed as a topically delivered treatment for mildly infected diabetic foot ulcers (iDFU) designed to reduce the risk of antimicrobial resistance (AMR).
- SECSEC Form 424B4 filed by Lakewood-Amedex Biotherapeutics Inc.424B4 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)
- SECSEC Form EFFECT filed by Lakewood-Amedex Biotherapeutics Inc.EFFECT - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)
- PRLakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for Phase 2 Clinical Trial of Nu-3Specialized CRO partnership supports Phase 2 program to advance Nu-3 toward potential registration pathway in large, underserved iDFU marketSARASOTA, Fla., May 12, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for locally treatable infectious diseases called the Bisphosphocin® class, today announced that it has entered into an agreement with Professional Education and Research Institute LLC (PERI) to serve as the contract research organization (CRO) for its upcoming Phase 2 clinical program of Nu-3, the Company's lead Bisphosphocin® product for the
- INSIDERSEC Form 4 filed by Director Tucker Joseph Edward4 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Issuer)
- INSIDERNew insider Tucker Joseph Edward claimed no ownership of stock in the company (SEC Form 3)3 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Issuer)
- INSIDERNew insider Deroma Leonard James claimed ownership of 187,736 units of Common Stock; $0.0001 par value (SEC Form 3)3 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Issuer)
- INSIDERNew insider Balzer Thomas claimed ownership of 255,322 units of Common Stock; $0.0001 par value (SEC Form 3)3 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Issuer)
- INSIDERNew insider Cooper Kelvin claimed ownership of 300,594 units of Common Stock; $0.0001 par value (SEC Form 3)3 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Issuer)
- INSIDERNew insider Ceccacci Peter claimed ownership of 468,148 units of Common Stock; $0.0001 par value (SEC Form 3)3 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Issuer)
- SECSEC Form S-1 filed by Lakewood-Amedex Biotherapeutics Inc.S-1 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)
- PRLakewood-Amedex Biotherapeutics Announces Positive Antimicrobial Resistance Data for Lead Candidate Targeting Infected Diabetic Foot UlcersNu-3 represents a novel class of potent, fast-acting, broad-spectrum antimicrobials called Bisphosphocins®SARASOTA, Fla., May 1, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT) a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced positive antimicrobial resistance (AMR) data for its lead compound, Nu-3, which is being developed as a topically delivered treatment for infected diabetic foot ulcers (iDFU). Nu-3 is one of a
- SECSEC Form 424B3 filed by Lakewood-Amedex Biotherapeutics Inc.424B3 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)
- SECLakewood-Amedex Biotherapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)
- PRLakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of DirectorsAppointment strengthens Board with seasoned public company biotech executive following recent Nasdaq direct listingSARASOTA, Fla., April 28, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced the appointment of Joseph Tucker, Ph.D., Chief Executive Officer of Enveric Biosciences (NASDAQ:ENVB), to its Board of Directors. Dr. Tucker's appointment follows Lakewood-Amedex Biotherapeutics' recent direct listing on Nasdaq and represents a key step in strengthening the Company's governance
LABT FAQ
2 questionsWhere does LABT stock trade?
Lakewood-Amedex Biotherapeutics Inc. (LABT) is listed on NASDAQ.How can I track LABT on Quantisnow?
Quantisnow aggregates Lakewood-Amedex Biotherapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LABT to receive live email and push alerts on every new disclosure.